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A B S T R A C T   
Systemic sclerosis (SSc) is a connective tissue disease secondary to three cardinal pathological features: immune- 
system alterations, diffuse microangiopathy, and fibrosis involving the skin and internal organs. The etiology of 
SSc remains quite obscure; it may encompass multiple host genetic and environmental -infectious/chemical- 
factors. 
The present review focused on the potential role of environmental agents in the etiopathogenesis of SSc based 
on epidemiological, clinical, and laboratory investigations previously published in the world literature. 
Among infectious agents, some viruses that may persist and reactivate in infected individuals, namely human 
cytomegalovirus (HCMV), human herpesvirus-6 (HHV-6), and parvovirus B19 (B19V), and retroviruses have 
been proposed as potential causative agents of SSc. These viruses share a number of biological activities and 
consequent pathological alterations, such as endothelial dysfunction and/or fibroblast activation. 
Moreover, the acute worsening of pre-existing interstitial lung involvement observed in SSc patients with 
symptomatic SARS-CoV-2 infection might suggest a potential role of this virus in the overall disease outcome. 
A variety of chemical/occupational agents might be regarded as putative etiological factors of SSc. In this 
setting, the SSc complicating silica dust exposure represents one of the most promising models of study. 
Considering the complexity of SSc pathogenesis, none of suggested causative factors may explain the appearance 
of the whole SSc; it is likely that the disease is the result of a multifactorial and multistep pathogenetic process. A 
variable combination of potential etiological factors may modulate the appearance of different clinical pheno-
types detectable in individual scleroderma patients. 
The in-deep investigations on the SSc etiopathogenesis may provide useful insights in the broad field of human 
diseases characterized by diffuse microangiopathy or altered fibrogenesis.   
1. Introduction 
Systemic sclerosis (SSc) can be counted among the most represen-
tative models of complex disease, involving the whole organism, from 
the skin to most of systems and internal organs [1–3]; it represents an 
open challenge for the physicians [1–4]. Commonly classified among 
connective tissue diseases, SSc is characterized by multiple pathogenetic 
mechanisms, mainly immune system alterations, diffuse micro-
angiopathy, and excessive production/deposition of extracellular matrix 
by altered fibroblasts [1,2]. All together, these pathological alterations 
may be responsible for both ischemic and fibrotic tissue damages 
causing cutaneous sclerosis, digital ulcers, pulmonary, cardiac, 
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gastrointestinal, and/or renal involvement [1–3]. The causative factors 
of the disease are still poorly understood; on the basis of 
clinico-epidemiological and laboratory investigations, it has been sug-
gested the contribution of both genetically driven host predisposition 
and environmental factors; the latter encompass both infectious agents 
and/or physico-chemical ‘toxic’ agents [5–12]. Numerous infectious 
agents have been suggested as possible causative factors of SSc; among 
viruses, those which persist and may reactivate in infected subjects, such 
as human cytomegalovirus (HCMV), human herpesvirus 6 (HHV-6), and 
parvovirus B19 (B19V) could be considered as the main candidates in 
the development of SSc. Moreover, some epidemiological studies 
focusing on occupational/environmental diseases, underlined the role of 
various physico-chemical toxic factors such as organic solvents, heavy 
metals, and crystalline silica [10–12]; this latter represents a good model 
of study of occupational autoimmune disorders since the first descrip-
tion of the association between scleroderma and silica dust exposure in 
male miners [13,14]. 
The present review focused on the potential role of environmental 
infectious/toxic agents in the etiopathogenesis of SSc evidenced 
throughout a careful search of epidemiological, clinical, and laboratory 
investigations reported in the world literature at June 2021 (PubMed, 
Embase, Scopus, and Web of Science). 
2. Infectious agents 
To date, increasing evidence has accumulated supporting a possible 
role of infectious agents as contributing factors in the etiology of SSc. In 
particular, higher occurrence of specific infections in SSc subjects, 
increased antibody and cell-mediated immune responses and molecular 
mimicry represent the most frequently evoked mechanisms by which 
microorganisms and/or viruses may contribute to the onset and devel-
opment of SSc [7,15–17]. 
2.1. Microorganisms 
Among microorganisms, Helicobacter pylori has been the most 
extensively studied due to its ubiquitous distribution and infection, even 
though conflictual conclusions were driven on its potential role. It has 
been speculated that the increased infection rates by this microorganism 
and higher antibody levels in SSc patients could be favored by the 
disturbed gastrointestinal motility occurring in these subjects and/or by 
a significant local inflammatory response to the gastric mucosa, which 
could potentially produce a systemic effect because of the alteration of 
systemic inflammatory mediators [18–21]. It has also been shown that 
Mycoplasma infection induces a scleroderma-like centrosome autoanti-
body response in mice [22]. Mayes and collaborators studied skin biopsy 
samples from SSc subjects by using a “pan bacteria” set of primers for a 
PCR assay in order to identify bacteria from a wide variety of prokary-
otic genera but no significant results were found supporting persistent 
bacterial infections in the pathogenesis of SSc [23]. 
As to protozoa, it has been described a significantly larger prevalence 
of anti–Toxoplasma gondii IgG and IgM antibodies in SSc patients [6]. To 
date, a larger body of evidence highlighting virus involvement as trig-
gering and/or worsening factors in SSc development is present in the 
Table 1 
Systemic sclerosis (SSc): main putative etiological factors, pathogenetic mechanisms and outcomes. VIRUSES.   
Immune system Ref. No. Endothelial cells Ref. No. Fibroblasts Ref. No.  




Significantly higher levels of 
antibodies against HCMV-derived 
UL94 protein in serum of SSc 
patients/Molecular mimicry between 
UL94 and self-peptides expressed on 
endothelial cells and dermal fibroblasts 
[44,50, 
52] 
Antibodies directed against UL94/ 
Recognition of membrane receptors of 
endothelial cells (NAG-2) with 
subsequent apoptosis of endothelial cells 
and expression of genes functionally 
associated with clinical signs of SSc 
(molecular mimicry mechanism) 
[44] Antibodies directed against 
UL94/Recognition of membrane 
receptors of dermal fibroblasts (NAG- 
2) with activation of fibroblasts and 
subsequent expression of genes 
functionally associated with clinical 
signs of SSc (molecular mimicry 
mechanism) 
[50] 
Significantly higher levels of 
antibodies against HCMV-derived 
protein pp65 in serum of SSc 
patients/Higher frequency of SSc- 
associated autoantibodies 
[36,51] Detection of viral transcripts in 
endothelial cells from skin biopsy 
of a woman with SSc diagnosed 
after an acute HCMV infection/ 
Possible triggering role for HCMV 
[49] Increased expression of pro- 
fibrotic factors/Fibrosis induction 
in fibroblasts 
[72] 
Increase of HCMV-specific CD8þ T 
cell responses in SSc patients vs 
healthy subjects/Statistically 
significant association with some of the 
most relevant disease parameters 
[65]   Increased expression of fibrosis- 
associated microRNAs/Fibrosis 





Increased prevalence/titer of anti- 
HHV-6 U94 antibodies/Multiple 
HHV-6 reactivations? 
[109] Increased expression of pro- 
fibrotic factors/Fibrosis induction in 
endothelial cells 
[109] Increased expression of pro- 
fibrotic factors/Fibrosis induction in 
fibroblasts 
[72] 
Impaired anti-HHV-6 NK 
response/Uncontrolled HHV-6 
infection and reactivation 
[109] Induction of HLA-G/Inhibition of 
angiogenesis 
[106] Increased expression of fibrosis- 
associated microRNAs/Fibrosis 




NLRP3 inflammasome activation/ 
Immune-mediated inflammatory tissue 
damages evolving in fibrosis 
[152] CACs apoptosis and impaired 
mobilization/Neo-vascularization 
defects, diffuse microangiopathy, 
ischemic tissue damages 
[124, 
148] 
Fibroblasts activation, increased 
migration, invasiveness and 
expression of profibrotic 
factors/Fibrosis induction in 
fibroblasts 
[146] 
Retroviruses Antibodies to retroviral proteins 
in sera from SSc patients. 
Sequence homologies between 
specific retroviral proteins and the 
topoisomerase I antigen (target of 
anti-Scl 70 antibodies)/Molecular 
mimicry 
[16] Experimentally induced 
expression of retroviral proteins in 
normal human dermal fibroblasts/ 
Acquisition of a SSc-like phenotype and 
production of extracellular matrix 
proteins 
[16]   
Abbreviations: UL94 (Unique Long HCMV genomic sequence encoded 94 KDa tegument protein); NAG-2 (Novel antigen-2); pp65 (65 KDa tegument phosphoprotein); 
U94 (HHV-6 unique gene 94 product); NK (Natural-killer cells); HLA-G (Human Leukocyte Antigen-G); NLRP3 (Nod-Like Receptor pyrin domain containing 3); CACs 
(Circulating angiogenic cells). 
C. Ferri et al.                                                                                                                                                                                                                                    
literature. 
2.2. Viruses 
Viruses are considered among the major environmental factors 
participating in the multifactorial development of SSc in genetically 
predisposed subjects. The present and subsequent chapters highlight the 
most significant results supporting virus involvement in the pathogen-
esis of SSc (Table 1, Fig. 1). 
Conflicting results on the potential role of human hepatitis B and 
hepatitis C viruses in SSc have been published, all lacking a clear 
pathogenetic mechanism, even though both viral agents have been 
described as involved in several autoimmune diseases [24–27]. 
Human papillomaviruses (HPVs) were also studied as possible co- 
factors in SSc development, but no solid conclusions are present to 
date, even though multi-HPV infections were found to be two times 
more frequent in SSc patients [28]. Interestingly, a very recent study 
showed a significant risk of SSc in subjects within the first year after HPV 
diagnosis, strengthening the hypothesis of such an association [29]. 
Furthermore, evidence supporting the role of retroviruses in SSc 
pathogenesis has been produced. Data include the demonstration of 
sequence homologies between specific retroviral proteins and the 
topoisomerase I antigen, which is the target of anti-Scl 70 antibodies in 
patients with SSc, thus evoking a molecular mimicry mechanism [16, 
30]. Moreover, the presence of antibodies to retroviral proteins have 
been detected in serum specimens from patients with SSc and it has been 
Fig. 1. Putative etiopathogenetic network of 
systemic sclerosis. The etiopathogenesis of 
systemic sclerosis (SSc) encompasses a 
genetically-driven predisposition with the 
possible contribution of epigenetic modifi-
cations, immune-system dysregulation, 
diffuse microangiopathy, and abnormal 
collagen tissue deposition by altered fibro-
blasts. These mechanisms are probably trig-
gered/sustained by variable combination of 
environmental factors (i.e.: infectious/phys-
ical/chemicals) through a multistep process. 
Briefly: (i) host genetic predisposing fac-
tors and epigenetic dysregulation have a 
prominent role in the SSc pathogenesis, 
commonly recognized but not plainly docu-
mented; (ii) remote events may precede 
even by years the clinical SSc onset; i.e. the 
exposure to toxic agents such as vinyl 
chloride or silica dust and/or latent viral 
infections, which may affect different target 
tissues: dendritic cells, macrophages, fibro-
blasts, endothelial, airway epithelial, 
immune-competent cells, and extracellular 
matrix. With respect to viral infections, they 
may trigger both innate and adaptive im-
mune system with T- and B-lymphocyte 
activation, antigen-dependent oligoclonal 
lymphocyte expansion, and specific autoan-
tibody production. The antigen-driven 
response (molecular mimicry mecha-
nism) has been suggested on the basis of 
sequence homologies between specific viral 
proteins and self-Ag (i.e.: HCMV protein 
UL94 and self-peptides NAG-2 expressed on 
endothelial cells and dermal fibroblasts, 
specific retroviral proteins and topo-I anti-
gen). Molecular mimicry can be responsible 
for both CD8+ T-lymphocyte and/or 
autoantibody-mediated endothelial/fibro-
blast injury, myofibroblast transition, with ischemic and fibrotic organ damage; (iii) endothelial dysfunction and apoptosis are crucial for both scleroderma 
vasculopathy and fibrogenesis. Endothelia are the primarily SSc target cells (reversible digital ischemia of Raynaud’s phenomenon is the presenting symptom of 
SSc in the majority of cases); a direct (viral infection, oxidative stress, toxic agents) or immune-mediated (AECA) endothelial cell damage may lead to severe vascular 
alterations (sub-endothelial fibrosis, muscular proliferation, and vessel deletion/thrombosis) and ultimately to ischemic lesions. B19V chronic infection of bone 
marrow might be responsible of impaired production of circulating EPCs with marked consequence for scleroderma microangiopathy. Endothelial to mesenchymal 
transdifferentiation may contribute to scleroderma fibrogenesis; several proinflammatory and profibrotic cytokines (TGF-β, CTGF, IL-1, TNF-α), chemokines, hyp-
oxia, and autoantibodies (AECA) can be involved in this process; (iiii) fibroblast transformation into pro-fibrotic phenotypes with collagen hyper-production 
and tissue accumulation may be the consequence of direct and/or immune-mediated (molecular mimicry) cell injury; the latter may be promoted by both viral 
infections and/or toxic agents such as cristallina silica. The myofibroblasts recruited from different sources (resident fibroblasts, bone marrow stem cells, and/or 
endothelial/epithelial to mesenchymal transdifferentiation) may concentrate at the extracellular matrix and produce excessive collagen accumulation with fibrotic 
organ damage. Abbreviations: HHV-6A: human herpes virus-6A; B19V: parvovirus B19; HCMV: human cytomegalovirus; UL94 (Unique Long HCMV genomic sequence 
encoded 94 KDa tegument protein); Ag: antigen; Abs: antibodies; vertical violet arrows (↑): increased levels; APC: antigen presenting cells; TH: T helper lymphocytes; 
AECA: anti-endothelial cell antibodies; anti-Topo I: anti-topoisomerase I (Scl70) Abs; anti-PDGFr: anti-platelet derived growth factor receptor Abs; TGF-β:trans-
forming growth factor beta; CTGF: connective tissue growth factor; IFN-γ: interferon gamma; IL: interleukin; TNF-α: tumor necrosis factor-α; NAG-2 (Novel antigen- 
2); ET1: endothelin 1; VEGF: vascular endothelial growth factor; ICAM: intercellular adhesion; PDGF: platelet derived growth factor; VCAM-1: type 1 vascular cell 
adhesion molecules; ROS: reactive oxygen species.   
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shown that the induced expression of retroviral proteins in normal 
human dermal fibroblasts results in the production of extracellular 
matrix proteins, acquiring a SSc-like phenotype [30]. 
The most significant experimental data were produced for specific 
viral agents which persist in the infected subject after primary infection 
and could reactivate during life, with particular regard to human cyto-
megalovirus (HCMV), human herpesvirus 6 (HHV-6) and parvovirus 
B19 (B19V). 
2.2.1. Herpesviruses 
Herpesviruses have been among the most studied viral agents for 
their putative role in the etiopathogenesis of SSc. 
Although they have often been described as possibly involved in a 
number of autoimmune diseases, for some of them, such as Varicella- 
Zoster virus quite isolated case reports have been described, often with 
controversial conclusions [31]. 
Concerning Epstein-Barr virus (EBV), besides some anecdotal clinical 
case [32,33], recent data provide the first evidence of infectious EBV in 
monocytes from patients with SSc and connect EBV to the activation of 
TLR8 and interferon innate immune response in freshly isolated SSc 
monocytes, suggesting a novel mechanism involving EBV as possible 
triggering agent of monocyte inflammation in SSc [34]. On the other 
hand, an increasing body of evidence is present concerning the two main 
human beta-herpesviruses, i.e. HCMV and HHV-6. The following 
sub-chapters describe the most relevant data supporting an important 
role of these viral agents in the pathogenesis of SSc, including the most 
recent data published by our group. 
2.2.1.1. Human cytomegalovirus (HCMV). A possible role of HCMV in 
the etiopathogenesis of SSc has been postulated on the basis of several 
evidences [5,7,8,35–40]. 
First of all, HCMV is able to infect in vivo both fibroblasts and 
endothelial cells, the main SSc target cells [41,42]. It is known that the 
apoptosis of endothelial cells and the abnormal activation of fibroblasts 
are prominent features of SSc, which could be also related to viral 
interference in the normal cell cycle progression [43,44]. In this regard, 
HCMV is able to modify the normal cell cycle in different ways, 
depending on the type of infected cells [45]; the involvement of specific 
viral proteins in the virus-induced cell cycle alterations has been 
demonstrated [46–48]. 
A relevant observation by Ferri and Collaborators, supporting a 
possible triggering role of HCMV in SSc development, has described the 
detection of HCMV transcripts in endothelial cells from a skin biopsy of a 
woman with SSc diagnosed after an acute HCMV infection [49]. 
Furthermore, a strong activation of virus-specific humoral immunity 
was observed, with significant prevalence of anti-HCMV serum anti-
bodies in SSc patients compared to healthy subjects, in particular 
directed against the immunodominant viral antigens, represented by the 
tegument phosphoprotein pp65 and the product of the viral UL94 gene 
[6,36,38,50,51]. To this regard, a molecular mimicry mechanism has 
been demonstrated, following the recognition of NAG-2 membrane re-
ceptors expressed on fibroblasts and endothelial cells by the antibodies 
directed against viral UL94. This interaction has been shown to induce 
activation of fibroblasts and apoptosis of endothelial cells with subse-
quent expression of genes functionally associated with clinical signs of 
SSc [44,50,52]. 
Several other pieces of evidence indicate that HCMV could also 
trigger the production of SSc-related autoantibodies [6,36,53,54]; 
Efthymiou and collaborators demonstrated that anti-HCMV antibodies 
levels are higher in specific autoantibody-positive SSc patients 
compared to seronegative cases [36] and, more recently, an association 
between anti-HCMV antibody responses and the SSc-related anti-Ro52 
autoantibody was observed [53]. 
As regards cell-mediated immunity, a significant contribution of T 
lymphocyte responses in the pathogenesis of SSc has been suggested, 
evoking their possible role in the modulation of fibrosis and vascular 
damage [40,55]. 
HCMV infection has a strong impact on the host’s immune system. In 
fact, the persistence of HCMV as a latent virus does not correspond to a 
silent condition, but rather is a source of continuous stimulation for the 
immune system, probably following subclinical reactivation cycles, 
mostly concerning virus-specific subsets of CD8+ T lymphocytes [56, 
57]. In particular, the CD8+ T lymphocytes in the peripheral blood of 
SSc patients exhibit an antigen-dependent oligoclonal expansion [58]. 
Interestingly, HCMV has been described as able to contribute to the 
expansion of specific subpopulations of CD8+ T lymphocytes with 
memory and effector phenotype in relation to increasing age (phe-
nomenon known as "memory inflation") as a result of repeated stimu-
lation by immunodominant viral peptides, including pp65 and IE1 
proteins of HCMV [59–64]. In this regard, viral-specific CD4+ and CD8+
T cell responses to the main immunogenic viral antigens pp65 and IE1 
have been deepened [65], highlighting the presence of HCMV 
antigen-driven CD8+ T cells (in particular, responsive to pp65 and IE1) 
in the blood of SSc patients where they were significantly more repre-
sented than in healthy controls. The same Authors found CD8+ T cell 
responses to the considered immunodominant viral antigens to be also 
significantly higher in SSc patients when compared to CD4+ T lym-
phocytes. Furthermore, they were connected to the disease duration, 
being significantly associated to a longer disease duration, as well as to 
the highest extent of cutaneous sclerosis assessed by modified Rodnan 
skin score, both connected to poorer patient outcomes [66–71]. 
More recent data have highlighted a relevant role of HCMV and 
HHV-6 in the induction of cell fibrosis and apoptosis at the tissue level, 
showing that both viruses significantly modified the expression of 
several pro-fibrotic and pro-apoptotic factors in in vitro infected human 
dermal fibroblasts [72]. Moreover, considering that miRNA expression 
has been found profoundly deregulated at the tissue level in SSc patients, 
the impact on cell microRNome of HCMV and HHV-6 infection in in vitro 
infected primary human dermal fibroblasts has been studied, finding 
that both viruses are able to significantly modulate miRNA expression 
involved in the disease [73]. It is worthy to note that several highly 
HCMV- and HHV-6-modulated pro-fibrotic factors and miRNA were 
reported to be involved in vivo in the multifactorial and multistep 
pathogenic process of SSc, thus reinforcing the notion of a putative role 
of these beta-herpesviruses in the etiopathogenesis of this autoimmune 
disease. 
2.2.1.2. Human herpesvirus 6 (HHV-6). Beside other infectious agents, 
the etiopathogenesis of SSc has also been associated with human 
herpesvirus 6 (HHV-6) infection [74]. HHV-6 belongs to the 
beta-herpesvirus subfamily, like HCMV with which it shares several 
features, including the ability to infect endothelial cells in vivo [75,76]. 
It infects humans very early in childhood, having a very high prevalence 
in the adult population worldwide [77]. Two species are recognized, 
HHV-6A and -6B, sharing high genome similarity, but differing for 
several biologic properties, cellular receptor, cellular tropism, epide-
miology, and disease association [78]. Originally classified as lympho-
tropic viruses, the in vivo tropism of both species is considerably broader, 
including T-lymphocytes, macrophages, natural killer (NK) cells, endo-
thelial cells, neurons, epithelial cells, thyrocytes, and endometrial cells 
[76,77,79–84]. 
After primary infection, causing exanthema subitum when sustained 
by HHV-6B infection [85], both viruses establish latent infection 
[86–89], and can reactivate symptomatically in the susceptible host, 
where reactivation has been associated to several autoimmune diseases, 
including systemic sclerosis [82,90–100]. 
Notably, HHV-6 was found to infect endothelial cells in vivo and in 
vitro [75], causing loss of their angiogenetic ability [76]. 
On the immunological side, the killer immunoglobulin-like receptor 
KIR2DL2 has been recently associated with a higher risk to develop SSc 
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[101], but it is also recognized as a factor impairing the anti-herpesvirus 
immune response, favoring herpesvirus infection [102–104]. Consis-
tently, an impaired NK response against HHV-6A/B was observed in 
multiple sclerosis patients expressing KIR2DL2 type [91]. Besides, 
HHV-6A/B infection can modulate the expression of the tolerogenic 
human leukocyte antigen (HLA)-G in different cell types including 
endothelial cells, where it mediates angiogenesis inhibition [105,106]; 
HLA-G was also increased in SSc patients compared to controls 
[107–109]. 
However, the hypothesized role of HHV-6 infection/reactivation in 
SSc development is still debated. 
Recent studies showed a significantly higher prevalence and load of 
HHV-6A/B DNA in both blood and peripheral tissues of SSc patients 
compared to controls, and a correlation between the viral load, disease 
severity and worse immunological markers, i.e. serum anti-Scl70 anti-
bodies [109]. Of note, the more tissue-tropic 6A species was detected in 
all skin biopsies, where it was actively replicating. Moreover, a higher 
anti-U94 antibody titer, increased levels of soluble HLA-G, and impaired 
NK response against the virus was found in SSc patients expressing 
KIR2DL2 receptors, according to previously published data [91,106, 
110]. Last, in vitro HHV-6 infected endothelial cells overexpressed 
several pro-fibrotic factors (i.e. GREM1, INHBE, IL4, IL5, TNF, MMP9), 
supporting the hypothesis that infection per se may interfere with the 
normal functions of endothelial cells [76,106]. Consistent with these 
findings, both circulating endothelial progenitor cells (EPC) with 
weakened angiogenic function [111] and regression of capillaries and 
small vessels commonly observed in SSc patients strongly suggest an 
impaired activity of endothelial cells in the microvascular homeostasis, 
although the specific mechanisms have not yet been elucidated. 
Similar to what observed with HCMV, as stated above, HHV-6 
infected dermal fibroblasts showed increased expression of pro-fibrotic 
factors and of miRNA specifically associated with induction of cell 
fibrosis, further supporting a possible role of HHV-6 in the fibrosis 
process [72,73]. 
Overall, the above virological and immunological data suggest that 
also HHV-6, and in particular the 6A species, might have a role in the SSc 
onset and/or progression. 
2.2.2. Human parvovirus B19 (B19V) 
Human parvovirus B19 (B19V) is a single-stranded DNA virus 
belonging to the Parvoviridae family. The virus is widely diffused and 
responsible for a broad range of clinical patterns, from asymptomatic or 
mild to severe, in some cases life-threatening manifestations [112]. The 
B19V shows a selective but not exclusive tropism for erythroid pro-
genitor cells in the bone marrow and, following a primary infection, can 
establish lifelong persistence in several tissues [113,114]. Whether this 
persistence is due to silent maintenance of viral genomes as episomes, or 
even integrated in the host genome, as recently observed in erythroid 
cells in vitro [115], is still unknown. It is supposed that changes in spe-
cific cellular environment or co-infection with other viruses could 
contribute to B19V expression [116–118]. 
Currently, the pathological potential of persistent virus on the 
cellular signaling pathways remains unclear. In non-erythroid tissues, 
the infection is usually abortive and the virus is presumed to exert its 
pathological role through indirect mechanisms, such as induction of 
inflammatory and autoimmune processes [119,120], or through 
virus-induced apoptosis mediated by the non-structural NS1 and 11 kDa 
proteins, by VP1 structural protein [121–124] or by phospholipase ac-
tivity of the VP1-unique region (VPu) of the B19V minor capsid protein 
[125]. 
Several reports have suggested that B19V plays a role in the etiology 
of autoimmune diseases [126]. The mechanisms involved in 
B19-associated autoimmunity include molecular mimicry [127,128], 
B19V-induced apoptosis with presentation of self-antigens to T lym-
phocytes [129,130] and the phospholipase activity of the B19V VP1 
protein which may contribute to the inflammatory processes induced by 
the production of leukotrienes and prostaglandins, and may also lead to 
the generation of unnatural cleavage products from cellular phospho-
lipids that may induce anti-phospholipid antibodies in combination with 
a distinct genetic background [126,131–135]. 
It has been demonstrated that, compared to healthy subjects, the SSc 
patients showed higher prevalence of B19V viremia [136] and/or higher 
persistence of B19V infection in the bone marrow and in the skin 
[137–140] as well as higher seroprevalence of anti-B19V NS1 anti-
bodies, a marker of persistent infection [138,141,142]. Moreover, B19V 
DNA can persist in SSc skin fibroblasts propagated in vitro [143]. 
Further, fibroblasts and perivascular inflammatory cells of the skin 
from SSc patients showed the presence of both B19V DNA and TNF-α 
mRNAs. The degree of B19V RNA expression correlated with endothelial 
cell degeneration and inflammation, suggesting a causal role of B19V in 
the propagation of the endothelial cell dysfunction [144]. 
In vitro studies provided evidence that B19V can infect the target cells 
of SSc such as dermal fibroblasts [145,146], endothelial cells from 
various tissues [145,147] but also different cell types belonging to the 
heterogenous group of marrow-derived circulating angiogenic cells 
(CACs) [124], which play a key role in vascular regeneration. B19V 
infection was associated with impaired endothelial regeneration 
through induction of apoptosis and dysregulated trafficking of infected 
CACs. These observations indicate that B19V infection can result in 
dysfunctional endogenous vascular repair [124,148,149]. 
There is evidence that chronic activation of the inflammasome and 
the production of IL1β have an important role in the induction of fibrosis 
[150,151]. Our recent studies suggest some possible mechanisms by 
which B19V could contribute to inflammation, fibrosis and vasculop-
athy. We demonstrated that B19V abortive infection induces 
NLRP3-mediated caspase-1 activation and IL-1β secretion in monocytic 
PMA-differentiated THP-1 cells and that B19V-infected monocytes from 
scleroderma patients show increased TNF-α production, NLRP3 
expression and caspase-1 activation [152]. 
Moreover, our recent investigations showed that B19V is able to 
activate in vitro normal dermal fibroblasts by increasing their ability of 
both migration and invasiveness, along with mRNA expression of 
different profibrotic genes (α-SMA, EDN-1, IL-6, TGF-β1 receptors 1 and 
2, Col1α2), some genes associated with inflammasome platform (AIM2, 
IFI16, IL-1β, CASP-1) and genes for some metalloproteases (MMP 2, 9 
and 12) [146]. These data suggest that B19V can activate dermal fi-
broblasts and may have a role in the pathogenesis of fibrotic lesions. 
Since it has been previously demonstrated that MMP12 overexpressed 
by SSc fibroblasts is able to induce impaired HMVECs proliferation, 
invasion, and capillary morphogenesis [153,154], B19V infection of 
NHDFs could contribute to the anti-angiogenic process, a pathological 
trait of SSc, responsible for the capillary loose and the subsequent 
ischemic organ injury [146]. 
Altogether, the recent investigations on B19V-driven biological al-
terations may give us novel insights into the in-depth mechanisms 
responsible for inflammation, fibroblast dysfunction and defective 
endothelial cell homeostasis of SSc. 
2.2.3. Severe acute respiratory syndrome coronavirus 2 
The ongoing pandemic caused by the novel coronavirus named se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was 
responsible for an illness termed coronavirus disease 2019 (Covid-19). 
Patients with autoimmune systemic diseases showed an increased 
prevalence of Covid-19 [155–158], particularly evident in SSc patients if 
compared to general population [159]. Scleroderma patients with 
pre-existing interstitial lung fibrosis showed a statistically higher prev-
alence of Covid-19 compared to those without. In these subjects 
Covid-19 was responsible of death in a significant number of hospital-
ized individuals because of severe pneumonia unresponsive to standard 
treatments [160]. 
Noteworthy, the pathological manifestations of Covid-19, namely 
interstitial lung involvement and diffuse microvascular thrombosis, are 
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comparable to the main manifestations of the SSc (1, 2 ?). These pre-
liminary observations may suggest a potential role of SARS-CoV-2 
infection, which may be provisionally considered as one of possible 
co-factor of worse disease outcome. Given the very recent appearance of 
this virus, only long-term follow-up of SARS-CoV-2 infected patients 
may clarify its actual (pathogenetic?) role in the natural course of SSc. 
3. Chemical agents 
During the last decades, several chemical agents have been suggested 
as potential etiologic agents of SSc. Among them, solvents, epoxy resins, 
welding fumes, pesticides, hair dyes, heavy metals, silicone breast im-
plants, and silica have been associated to SSc development [161]. 
Since 1914, many anecdotal observations have highlighted the role 
of solvents in SSc [13,14], reinforced by important epidemiological data 
focusing on exposure to solvents in general [162]. The latter was asso-
ciated to the increased risk of developing SSc, predominantly in male 
gender [9]. In addition, several studies reported detailed data on specific 
solvents such as toluene, xylene, trichloroethylene, chlorinated solvents, 
epoxy resins, paint thinners, and removers, as possible triggering agents 
of SSc [9]. In particular, trichloroethylene exposure was observed in 
male patients with serum anti-topoisomerase I antibodies, suggesting its 
ability to trigger a specific autoimmune response in genetically sus-
ceptible individuals [9,11]. Furthermore, the exposure to some solvent 
combinations such as xylene, toluene, and acetone appeared to confer an 
increased risk to develop SSc. Few studies have focused on the patho-
genetic role of occupational exposure to welding fumes; in particular, a 
large case series of 100 SSc patients showed a significant association 
with SSc development [11]. 
Pesticides were also associated to SSc; their role was strongly sug-
gested by the anecdotal observation of 2 children with generalized 
cutaneous sclerosis following the exposure to pesticides containing 
malathion and diniconazole [163]. While data regarding hair dyes and 
cosmetic products were insufficient to demonstrate a causative role in 
the development of SSc, some epidemiological data proposed their 
possible role in autoimmune diseases [164]. 
Since 1988, heavy metals were suspected to be involved in SSc [164]; 
later studies demonstrated significant high levels of antimony, cad-
mium, lead, and mercury in hair samples of SSc patients [9,11]. 
Finally, numerous silicon compounds, i.e. crystalline silica, asbestos, 
silica nanoparticles, and silicone, may stimulate autoimmune reactions 
in humans [165]. The following paragraphs focus on silicone breast 
implants (SBI) and crystalline silica; the latter represents one of the most 
important models of SSc triggered by environmental chemical agent 
(Table 2). 
3.1. Silicone breast implants 
The silicone breast implants (SBI) procedures were introduced since 
the 1960s; subsequently, a possible causative role of SBI in the devel-
opment of some connective tissue diseases has been suggested [166]. In 
particular, the first description of SSc complicating augmentation 
mammoplasty dated back to 1979 [167]; however, a clear-cut evidence 
of such causal association was never demonstrated [168]. It was there-
fore assumed instead that the SBI may trigger a number of symptoms 
that do not meet the classification criteria of any specific autoimmune 
disease. This intriguing phenomenon was termed siliconosis, which may 
be included in the autoimmune syndrome induced by adjuvants, the 
so-called ASIA syndrome or Shoenfeld’s syndrome, potentially triggered 
by implanted biomaterials in genetically predisposed subjects [10,169, 
170]. 
3.2. Silica 
Occupational exposure to silica-containing dust has been proposed as 
a possible risk factor of some systemic autoimmune diseases, including 
rheumatoid arthritis, systemic lupus erythematosus, ANCA-associated 
vasculitis, and SSc [10,161–171]. In particular, the association be-
tween SSc and exposure to silica dust, the so-called ’Erasmus syndrome’, 
was proposed in 1957, although it has been first described by Byrom 
Bramwell in 1914 in a small series of five stonemasons, one coal-miner 
and a coppersmith [13,14]. During the following years, several epide-
miologic studies and reviews evidenced the possible link between SSc 
and silica exposure [161,167,171]. In particular, SSc association with 
silica was found to have a higher incidence in men as a consequence of 
specific chronic or long term exposure [172]. Interestingly, the presence 
of serum anti-Scl70 autoantibodies has shown to characterize the 
scleroderma subjects exposed to silica dust [173]; the production of 
these specific autoantibodies could be triggered by silica particles, 
which are capable of acting as an adjuvant to the immune system [174]. 
In addition, molecular biology studies evidenced that silica particles 
may be able to yield specific immune-system alterations with wide 
cytokine production and inflammasome activation, which in turn may 
promote extensive tissue remodeling and fibrogenesis [175]. 
Comparable pathogenetic mechanisms might be operative in the 
setting of SSc patients with clinical history of silica exposure and specific 
genetic susceptibility, either in the early, pre-scleroderma stage or even 
during the multistep course of disease progression. In this scenario, the 
crosstalk between fibroblasts and inflammatory cells induced by silica 
might be related to specific disease phenotypes [173–176]. In fact, 
silica-exposed individuals present important alterations in their immune 
response when compared to controls, with increased serum IL-2 receptor 
Table 2 
Systemic sclerosis (SSc): main putative etiological factors, pathogenetic mechanisms and outcomes. CHEMICALS.   
Immune system Ref. No. Endothelial cells Ref. No. Fibroblasts Ref. No. 
Mechanisms/Effects Mechanisms/Effects Mechanisms/Effects 
Silica 
(Si) 
IL-2 receptor decrease, increase of IFN- 
gamma, IL-1β, TNF-alfa, IL-6, IL-10 and 
TGF-β cytokines/Immune activation and 
lymphoproliferation 
[175] IL-8 release/Cytotoxic effect in mono- 
and in coculture with A549 alveolar 
epithelial cells and microvascular cells 
[177] Si induced macrophages miRNAs led 
to myofibroblast transition/Critical 
role in lung damage and fibrosis 
[181] 
NALP3 inflammasome-driven IL-1β 
increase, Scavenger receptors activation, 
macrophages apoptosis/Inflammasome 
activation, lung inflammation and fibrosis, 
silicosis 
[178] Si O2-induced increased cell 
proliferation, migration, and changes 
in endothelial cells; increased 
expression of mesenchymal markers/ 
Lung fibrosis 
[179] Silica gel induced collagen and MAP 
kinase phosphorylation on human 
dermal fibroblasts/Silica gel directly 
cause fibrotic phenotype 
[182] 
Si NPs trigger cytokine inflammatory 
response and induce oxidative stress/ 
Inflammation of human peripheral blood 
mononuclear cells 
[176] Si NPs induced significant calcium 
mobilization and ROS generation/ 
Decreased the viability and damaged the 
plasma membrane of cultured HUVECs 
[180] Si NPs lead to cell necrosis in a dose- 
dependent manner/Fibroblast cell 
necrosis 
[183] 
Abbreviations: IL (interleukin); TGF (transforming growth factor); IFN (interferon); TNF (tumor necrosis factor); NALP (nucleotide-binding oligomerization domain, 
leucine rich repeat and pyrin domain containing); NPs (nanoparticles); ROS (reactive oxygen species); HUVEC (human umbilical vein endothelial cells); miRNA 
(microRNA); MAP kinase (mitogen-activated protein kinase). 
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levels, decreased production of IL-2 and increased levels of the 
pro-inflammatory (IFN-gamma, IL-1β, TNF-alfa, IL-6) as well as 
anti-inflammatory (IL-10 and TGF-β) cytokines. This condition leads to 
enhanced lymphoproliferative responses in these individuals [174]. The 
inflammatory response following exposure to silica is mediated by 
NALP3 inflammasome-driven IL-1β and the binding of silica to scav-
enger receptors also results in apoptosis of macrophages and the release 
of mediators (e.g., proinflammatory cytokines) contributing to lung 
inflammation and fibrosis [175]. Thus, silica dust inhalation might be 
particularly relevant for the possible contribution in the lung involve-
ment that may affect the overall SSc patient’s disease outcome [173, 
174]. 
The hypothesis of a pathogenetic role of silica in human diseases is 
strongly supported by laboratory investigations [176–183]; recently, 
silica nanoparticles have been reported to be able to induce oxidative 
stress and mediated apoptosis mainly via the intrinsic or mitochondrial 
pathway (caspase-dependent pathway) in a size- and dose-dependent 
manner [176]. ROS-mediated toxicity is believed to be an important 
mechanism of the silica particles toxicity, particularly of their 
pro-inflammatory effect observed in human peripheral blood mono-
nuclear cells. Several studies demonstrated the capacity of silica nano-
particles to increase cytokine production from PBMC, human lung 
epithelial cells, and human endothelial cell lines [176,177]. Repeated 
intravenous administrations of silica nanoparticles in mice were found 
to induce pulmonary inflammation and collagen accumulation via 
JAK2/STAT3 and TGF-β/Smad3 pathways in vivo [178]. Moreover, they 
were able to promote in vitro the trans differentiation of circulating 
mouse fibrocytes into myofibroblasts in dose- and time-dependent 
manner, also increasing the protein and mRNA expression levels of 
collagen-I, collagen-III and α-SMA [179,180]. In vitro silica was also 
found to directly cause fibrotic phenotype and fibroblast cell necrosis 
[181–183]. 
In addition to previous clinico-epidemiological studies, our recent 
investigation further supports the possible role of silica as pathogenetic 
co-factor of SSc [184]. In a series of unselected scleroderma patients, 
resident in the same geographical area with high density of industries, 
individuals with anamnestic exposure to silica dust showed significantly 
higher serum levels of silicon along with a higher prevalence of some 
disease manifestations, i.e. diffuse cutaneous SSc, myositis, and/or 
interstitial lung involvement, compared to those without silica exposure. 
Interestingly, serum levels of silicon element correlated with the severity 
of lung fibrosis, evaluated by means of high-resolution computed to-
mography and respiratory function tests [185]. Moreover, serum levels 
of silicon significantly correlated with levels of inflammation reactants, 
i.e. ESR and CRP, and anti-Scl70 autoantibody seropositivity. All 
together, these findings first demonstrated a significant correlation be-
tween circulating silica particles and some SSc worse prognostic pa-
rameters in patients’ series from a particular geographic area. 
4. Discussion 
The SSc is a connective tissue disease whose origin remains still 
largely unknown. The absence of animal models able to recapitulate the 
full clinical picture of SSc [1] along with the limited knowledge 
regarding the actual causative factors hamper the clear definition of the 
whole etiopathogenetic process of the disease [1–4]. 
The present review analyzed the etiopathogenetic role of the main 
environmental factors in SSc patients, with the contribution of genetic 
factors as suggested by several clinical observations and laboratory in-
vestigations [186,187]. The most relevant genetic association for SSc 
concerns the MHC region, with HLA and non- HLA genes being involved 
in various functions, including B and T cell activation and innate im-
munity, extracellular matrix deposition, cytokines, and autophagy. In 
addition to genetic predisposition, also epigenetic modifications leading 
to heritable phenotypes can influence and contribute to the develop-
ment of SSc [186,187]. Our aforementioned case report of a young lady, 
whose mother had a systemic lupus erythematosus, developing SSc after 
HCMV infection [49] represents a strong clue as regards the synergistic 
effects of host genetic background and specific environmental causative 
factors. 
It is likely that they are not mutually exclusive, each of them could 
operate at different steps of the pathogenetic process by interfering with 
one or more biological components of the complex network, i.e. lym-
phocytes, fibroblasts, and/or endothelia. 
Focusing on exogenous etiological factors of SSc, data reported in the 
literature encompass numerous potential infectious and chemical agents 
identified on the basis of anecdotal observations, epidemiological 
studies, generally limited to small patients’ series insufficient for defi-
nite conclusions, and laboratory investigations that evidenced their 
ability to evoke some peculiar mechanisms of disease [1,2,6–12,188]. 
However, we are facing a fragmented mosaic; at the present there is no 
definite evidence about the actual role of a single agent and its place in 
the natural history of the disease. 
Only rare case reports or limited patients’ series pointed out the 
possible causative role of specific infectious/chemical agent, generally 
in the presence of the host, familiar/occupational predisposing condi-
tions [1–13,17,189]. Therefore, we can reasonably hypothesize that on 
the basis of host-related conditions, one or more environmental factors 
might contribute to the appearance and/or progression of scleroderma 
disease. The putative network that brings together the above potential 
etiopathogenetic components is shown in Fig. 1. 
The actual role of various etiopathogenetic factors, as well as their 
intervention in the natural course of the disease are very difficult to be 
correctly defined. A schematic representation of the etiopathogenetic 
network should integrate a number of definite knowledge and other 
potential elements. Some remote events may precede the clinical onset 
of SSc, even of years; namely, long-lasting exposure to toxic agents such 
as silica dust and/or latent viral infections; they may affect one or more 
target tissues, i.e. macrophages, fibroblasts, dendritic, endothelial, 
epithelial, immune-competent cells, and extracellular matrix, with 
consequent innate and adaptive immune system response. Beside the 
host genetic susceptibility, other conditions may prompt the SSc onset or 
exacerbate its clinical course; namely, psychic and physical stressful 
events, pregnancy, intercurrent infections, or neoplastic process, which 
may contribute to the immune-system imbalance. 
Single causative factors may be associated to specific target cells and 
disease mechanisms; however, different etiological agents may share the 
same pathogenetic pathway and relative tissue damages (Fig. 1). 
As regards virus-driven immunopathological mechanisms evoked to 
support their involvement in SSc etiopathogenesis, as detailed above, in 
Table 1 and Fig. 1, they are mainly focused on: i) molecular mimicry, 
demonstrated, e.g., for HCMV and retrovirus specific antigens and 
endothelial and fibroblast receptors, leading to auto-antibodies against 
the aforementioned cells; as a consequence, molecular mimicry can be 
responsible for both CD8+ T-lymphocyte and/or autoantibody-mediated 
endothelial/fibroblast injury, myofibroblast transition, with ischemic 
and fibrotic organ damage; ii) virus-triggered adaptive and innate 
immune-mediated inflammatory tissue damages evolving in fibrosis and 
endothelial cell damages and apoptosis (e.g. HCMV, HHV-6A, B19V); iii) 
virus triggered expression of pro-fibrotic factors (e.g. HCMV, HHV-6A, 
B19V); iiii) virus triggered expression of pro-fibrotic microRNA (e.g. 
HCMV, HHV-6A) [16,36,44,49–52,65,73,106,109,124,146,148,152]. 
Concerning the putative involvement of toxic factors, in particular 
silica, in the etiopathogenesis of SSc, as detailed in the dedicated 
chapters (see also Table 2), the past and recent literature data have 
highlighted: i) the production of specific autoantibodies (in particular 
anti-Scl70), silica particles acting as an adjuvant to the immune system; 
ii) the ability of silica particles to induce specific immune-system al-
terations with wide cytokine production from PBMC, human lung 
epithelial cells, human endothelial cells and inflammasome activation, 
which in turn may promote extensive tissue remodeling and fibro-
genesis; iii) the binding of silica to scavenger receptors that results in 
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apoptosis of macrophages and release of mediators contributing to lung 
inflammation and fibrosis; iiii) the ability of silica nanoparticles to 
induce oxidative stress and mediated apoptosis; iiiii) significantly higher 
serum levels of silicon along with a higher prevalence of some disease 
manifestations, i.e. diffuse cutaneous SSc, myositis, and/or interstitial 
lung involvement in SSc individuals with anamnestic exposure to silica 
dust [175–180,182,183]. 
The SSc is characterized by a broad phenotypic variability and un-
predictable clinical course, commonly observed among patients and in 
individual cases during long-term follow-up, which are related to the 
multifactorial and multistep etiopathogenesis of the disease (Fig. 2) 
[1–4,184,188]. Indeed, patients presenting with severe cutaneous 
and/or visceral organ involvement may show a very slow progression 
during the clinical follow-up; vice versa other subjects may show a mild 
SSc variant that later may evolve, even abruptly, towards serious disease 
manifestations. In many cases, a mild clinical course can be studded by 
sudden onset of one or more organ damages that may affect the overall 
prognosis of the disease. These events can be triggered by subsequent 
causative factors at any times of the natural history of SSc; they may 
affect both the extension of skin sclerosis and presence/severity of 
visceral organ involvement, mainly cutaneous ulcers, pulmonary hy-
pertension, cardiomyopathy, scleroderma renal crisis, and interstitial 
lung fibrosis (Fig. 2). In this respect, the rapid worsening of pre-existing 
interstitial lung involvement, observed during the ongoing pandemic in 
some SSc patients infected by SARS-CoV-2, represents an example of the 
possible pathogenetic role of concurring factors during the natural 
course of the disease able to affect its overall prognosis [157–160]. 
In the next future, careful clinical observation and multidisciplinary 
approach might also contribute to a better comprehension of SSc etio-
logical factors. In-depth laboratory investigations focusing on adequate 
series of patients selected at particular stages of the disease, namely very 
early SSc, rapidly worsening and/or recent onset of specific new 
symptom(s), should be critical to clarify the actual role of putative 
etiological factors. In this context, the SSc can be considered an 
important model of study due to the complex of multiple causative 
factors and pathological alterations; therefore, a better understanding of 
the etiopathogenetic mechanisms involved in SSc could provide 
valuable insights also in other systemic autoimmune disorders and in the 
broader field of human diseases characterized by increased fibrogenesis 
and/or diffuse microangiopathy. 
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A. Balbir-Gurman, Y. Braun-Moscovici, N. Hunzelmann, R. Pellerito, 
P. Caramaschi, C. Black, N. Damjanov, J. Henes, V.O. Santamaria, S. Heitmann, 
M. Seidel, J.A. Pereira Da Silva, B. Stamenkovic, C.F. Selmi, M. Tikly, L. 
N. Denisov, U. Müller-Ladner, M. Engelhart, E. Hachulla, V. Riccieri, R. 
M. Ionescu, C. Mihai, C. Sunderkötter, A. Kuhn, G. Schett, J. Distler, P. Meroni, 
F. Ingegnoli, L. Mouthon, F. De Keyser, V. Smith, F.P. Cantatore, A. Corrado, 
S. Ullman, L. Iversen, M.R. Pozzi, K. Eyerich, R. Hein, E. Knott, P. Wiland, 
M. Szmyrka-Kaczmarek, R. Sokolik, E. Morgiel, M. Madej, J.J. Alegre-Sancho, 
B. Krummel-Lorenz, P. Saar, M. Aringer, C. Günther, E. Anne, R. Westhovens, 
E. De Langhe, J. Lenaerts, B. Anic, M. Baresic, M. Mayer, M. Üprus, K. Otsa, 
S. Yavuz, S.C. Radominski, C. de Souza Müller, V.F. Azevedo, S. Popa, T. Zenone, 
S. Stebbings, J. Highton, A. Mathieu, A. Vacca, L. Stamp, P. Chapman, 
J. O’donnell, K. Solanki, A. Doube, D. Veale, M. O’rourke, E. Loyo, M. Li, 
E. Rosato, A. Amoroso, A. Gigante, F. Oksel, F. Yargucu, C.M. Tanaseanu, 
M. Popescu, A. Dumitrascu, I. Tiglea, R. Foti, E. Visalli, A. Benenati, G. Amato, 
C. Ancuta, R. Chirieac, P. Villiger, S. Adler, D. Dan, P.G. de la Peña Lefebvre, S. 
R. Rubio, M.V. Exposito, J. Sibilia, E. Chatelus, J.E. Gottenberg, H. Chifflot, 
I. Litinsky, F. Del Galdo, A. Venalis, L.A. Saketkoo, J.A. Lasky, E. Kerzberg, 
F. Montoya, V. Cosentino, M. Limonta, A.L. Brucato, E. Lupi, F. Spertini, C. Ribi, 
G. Buss, T. Martin, A. Guffroy, V. Poindron, L. Chung, T. Schmeiser, P. Zebryk, 
N. Riso, G. Riemekasten, E. Rezus, P. Sarzi Puttini, Predictors of disease 
worsening defined by progression of organ damage in diffuse systemic sclerosis: a 
European Scleroderma Trials and Research (EUSTAR) analysis, Ann. Rheum. Dis. 
78 (2019) 1242–1248, https://doi.org/10.1136/annrheumdis-2019-215145. 
[67] D. Khanna, D.E. Furst, P.J. Clements, Y. Allanore, M. Baron, L. Czirjak, O. Distler, 
I. Foeldvari, M. Kuwana, M. Matucci-Cerinic, M. Mayes, T. Medsger, P.A. Merkel, 
J.E. Pope, J.R. Seibold, V. Steen, W. Stevens, C.P. Denton, Standardization of the 
modified Rodnan skin score for use in clinical trials of systemic sclerosis, 
J. Scleroderma Relat. Disord. 2 (2017) 11–18, https://doi.org/10.5301/ 
jsrd.5000231. 
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with Sjögren’s Syndrome, J. Autoimmun. 2 (1989) 449–455, https://doi.org/ 
10.1016/0896-8411(89)90174-1. 
[91] R. Rizzo, V. Gentili, I. Casetta, E. Caselli, R. De Gennaro, E. Granieri, E. Cassai, 
D. Di Luca, A. Rotola, Altered natural killer cells’ response to herpes virus 
infection in multiple sclerosis involves KIR2DL2 expression, J. Neuroimmunol. 
251 (2012) 55–64, https://doi.org/10.1016/j.jneuroim.2012.07.004. 
[92] F. Broccolo, F. Drago, G. Cassina, A. Fava, L. Fusetti, B. Matteoli, L. Ceccherini- 
Nelli, M.G. Sabbadini, P. Lusso, A. Parodi, M.S. Malnati, Selective reactivation of 
C. Ferri et al.                                                                                                                                                                                                                                    
human herpesvirus 6 in patients with autoimmune connective tissue diseases, 
J. Med. Virol. 85 (2013) 1925–1934, https://doi.org/10.1002/jmv.23670. 
[93] G.R.F. Krueger, C. Sander, A. Hoffmann, A. Barth, B. Koch, M. Braun, Isolation of 
human herpesvirus-6 (HHV-6) from patients with collagen vascular diseases, in: 
Vivo (Brooklyn) vol. 5, 1991, pp. 217–225. https://europepmc.org/article/med/ 
1654147. (Accessed 1 September 2021). 
[94] S. Ranger-Rogez, E. Vidal, F. Liozon, F. Denis, Primary sjögren’s syndrome and 
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A. Miliar-García, Expression of NLRP3 inflammasome, cytokines and vascular 
mediators in the skin of systemic sclerosis patients, Isr. Med. Assoc. J. 17 (2015) 
5–10. 
[152] K. Zakrzewska, R. Arvia, M.G. Torcia, A.M. Clemente, M. Tanturli, G. Castronovo, 
G. Sighinolfi, D. Giuggioli, C. Ferri, Effects of parvovirus B19 in vitro infection on 
monocytes from patients with systemic sclerosis: enhanced inflammatory 
pathways by caspase-1 activation and cytokine production, J. Invest. Dermatol. 
139 (2019) 2125–2133, https://doi.org/10.1016/j.jid.2019.03.1144, e1. 
[153] S. D’Alessio, G. Fibbi, M. Cinelli, S. Guiducci, A. Del Rosso, F. Margheri, S. Serratì, 
M. Pucci, B. Kahaleh, P. Fan, F. Annunziato, L. Cosmi, F. Liotta, M. Matucci- 
Cerinic, M. Del Rosso, Matrix metalloproteinase 12-dependent cleavage of 
urokinase receptor in systemic sclerosis microvascular endothelial cells results in 
impaired angiogenesis, Arthritis Rheum. 50 (2004) 3275–3285, https://doi.org/ 
10.1002/art.20562. 
[154] S. Serratì, M. Cinelli, F. Margheri, S. Guiducci, A. Del Rosso, M. Pucci, G. Fibbi, 
L. Bazzichi, S. Bombardieri, M. Matucci-Cerinic, M. Del Rosso, Systemic sclerosis 
fibroblast inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the 
endothelial cell urokinase receptor, J. Pathol. 210 (2006) 240–248, https://doi. 
org/10.1002/path.2048. 
[155] G. Emmi, A. Bettiol, I. Mattioli, E. Silvestri, G. Di Scala, M.L. Urban, A. Vaglio, 
D. Prisco, SARS-CoV-2 infection among patients with systemic autoimmune 
diseases, Autoimmun. Rev. 19 (2020), https://doi.org/10.1016/j. 
autrev.2020.102575. 
[156] C. Ferri, D. Giuggioli, V. Raimondo, M. L’Andolina, A. Tavoni, R. Cecchetti, 
S. Guiducci, F. Ursini, M. Caminiti, G. Varcasia, P. Gigliotti, R. Pellegrini, 
D. Olivo, M. Colaci, G. Murdaca, R. Brittelli, G.P. Mariano, A. Spinella, 
S. Bellando-Randone, V. Aiello, S. Bilia, D. Giannini, T. Ferrari, R. Caminiti, 
V. Brusi, R. Meliconi, P. Fallahi, A. Antonelli, COVID-19 and rheumatic 
autoimmune systemic diseases: report of a large Italian patients series, Clin. 
Rheumatol. 39 (2020) 3195–3204, https://doi.org/10.1007/s10067-020-05334- 
7. 
[157] D. Marotto, P. Sarzi-Puttini, What is the role of rheumatologists in the era of 
COVID-19? Autoimmun. Rev. 19 (2020) https://doi.org/10.1016/j. 
autrev.2020.102539. 
[158] F. Ursini, P. Ruscitti, S. D’Angelo, F. Cacciapaglia, R. De Angelis, C. Campochiaro, 
F. Caso, M. De Santis, I. Di Cola, S. Parisi, V. Raimondo, G. Abignano, L. Costa, 
J. Ciaffi, L. Dagna, A. Iagnocco, F. Iannone, R. Meliconi, R. Giacomelli, C. Ferri, 
Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in 
adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease 
Italian study group, Ann. Rheum. Dis. 0 (0) (2021) 1–3, https://doi.org/10.1136/ 
annrheumdis-2021-220606. 
[159] C. Ferri, D. Giuggioli, V. Raimondo, L. Dagna, V. Riccieri, E. Zanatta, S. Guiducci, 
A. Tavoni, R. Foti, G. Cuomo, R. De Angelis, F. Cozzi, G. Murdaca, I. Cavazzana, 
N. Romeo, V. Codullo, F. Ingegnoli, R. Pellegrini, G. Varcasia, A. Della Rossa, 
M. De Santis, G. Abignano, M. Colaci, M. Caminiti, M. L’Andolina, E. Lubrano, 
A. Spinella, F. Lumetti, G. De Luca, S. Bellando-Randone, E. Visalli, S. Bilia, 
D. Giannini, F. Masini, G. Pellegrino, E. Pigatto, E. Generali, F. Dall’Ara, G. 
P. Mariano, S. Barsotti, G. Pettiti, G. Zanframundo, R. Brittelli, V. Aiello, 
D. Scorpiniti, T. Ferrari, R. Caminiti, C. Campochiaro, S. D’Angelo, F. Iannone, 
M. Matucci-Cerinic, A. Doria, M. Miccoli, P. Fallahi, A. Antonelli, A. Della Rossa, 
G. Pagano Mariano, R. Cecchetti, P. Gigliotti, D. Olivo, F. Ursini, V. Brusi, 
R. Meliconi, R. Scarpa, E. Fusaro, A.L. Zignego, S.R. Paparo, F. Ragusa, G. Elia, S. 
M. Ferrari, COVID-19 and systemic sclerosis: clinicopathological implications 
from Italian nationwide survey study, Lancet Rheumatol 3 (2021) e166–e168, 
https://doi.org/10.1016/S2665-9913(21)00007-2. 
[160] P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, 
COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet 
395 (2020) 1033–1034, https://doi.org/10.1016/S0140-6736(20)30628-0. 
[161] C.G. Parks, K. Conrad, G.S. Cooper, Occupational exposure to crystalline silica 
and autoimmune disease, in: Environ. Health Perspect, Environ Health Perspect, 
1999, pp. 793–802, https://doi.org/10.1289/ehp.99107s5793. 
[162] F.W. Miller, L. Alfredsson, K.H. Costenbader, D.L. Kamen, L.M. Nelson, J. 
M. Norris, A.J. De Roos, Epidemiology of environmental exposures and human 
autoimmune diseases: findings from a national institute of environmental health 
sciences expert panel workshop, J. Autoimmun. 39 (2012) 259–271, https://doi. 
org/10.1016/j.jaut.2012.05.002. 
[163] B. Sozeri, N. Gulez, G. Aksu, N. Kutukculer, T. Akalin, G. Kandiloglu, Pesticide- 
induced scleroderma and early intensive immunosuppressive treatment, Arch. 
Environ. Occup. Health 67 (2012) 43–47, https://doi.org/10.1080/ 
19338244.2011.564231. 
[164] L.M. Pedersen, H. Permin, Rheumatic disease, heavy-metal pigments, and the 
great masters, Lancet 331 (1988) 1267–1269, https://doi.org/10.1016/S0140- 
6736(88)92082-X. 
[165] K.M. Pollard, Silica, silicosis, and autoimmunity, Front. Immunol. 7 (2016) 97, 
https://doi.org/10.3389/fimmu.2016.00097. 
[166] E.C. Janowsky, L.L. Kupper, B.S. Hulka, Meta-analyses of the relation between 
silicone breast implants and the risk of connective-tissue diseases, N. Engl. J. Med. 
342 (2000) 781–790, https://doi.org/10.1056/nejm200003163421105. 
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